The use of terbinafine in the treatment of tinea cruris Review article
Article Sidebar
Published:
Jun 30, 2017
Keywords:
terbinafine, mycoses, tinea cruris, treatment
Main Article Content
Abstract
Terbinafina has been used in Tinea corporis, Tinea cruris, Tinea pedis and Tinea unguium (Onychomycosis). Therapy with this preparation is considered to be very effective and safe. Terbinafine has an efficacy of over 80% for the treatment of onychomycosis. The drug is well tolerated by patients and side effects are a minor problem. It makes terbinafine useful in everyday practice.
Article Details
How to Cite
Wojciechowska-Zdrojowy, M., & Szepietowski, J. (2017). The use of terbinafine in the treatment of tinea cruris. Medycyna Faktow (J EBM), 10(2(35), 110-114. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2151
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Braun-Falco O., Plewig G., Wolff H.H. et al.: Dermatologia. Tom I. Czelej, Lublin 2010.
2. Rotsztejn H., Zalewska A.: Superficial tinea infections of the genital region in women. Przegl. Menopauz. 2005; 4: 65-67.
3. Kaszuba A., Adamski Z.: Leksykon dermatologiczny. Wyd. I. Czelej, Lublin 2011.
4. Iwanaga T., Ushigami T., Anzawa K., Mochizuki T.: Pathogenic Dermatophytes Survive in Nail Lesions During Oral Terbinafine Treatment for Tinea Unguium. Mycopathologia 2017. DOI: 10.1007/s11046-017-0118-8 [Epub ahead of print].
5. Maleszka R., Adamski Z., Szepietowski J., Baran E.: Leczenie powierzchownych zakażeń grzybiczych – rekomendacje ekspertów Sekcji Mikologicznej Polskiego Towarzystwa Dermatologicznego. Przegl. Dermatol. 2015; 102: 305-315.
6. Hasse-Cieślińska M.: Diagnostyka i leczenie powierzchownych zakażeń grzybiczych. Przew. Lek. 2006; 7: 109-120.
7. Hasse-Cieślińska M.: Nowoczesne leki stosowane w terapii dermatomikoz. Przew. Lek. 2004; 6: 70-77.
8. Maleszka R., Adamski Z.: Leki przeciwgrzybicze w codziennej praktyce lekarskiej. Przew. Lek. 2001; 4: 48-56.
9. Khoza S., Moyo I., Ncube D.: Comparative hepatotoxicity of fluconazole, ketoconazole, itraconazole, terbinafine, and griseofulvin in rats. J. Toxicol. 2017; 2017: 6746989.
10. Patel G.A., Wiederkehr M., Schwartz R.A.: Tinea cruris in children. Cutis. 2009; 84: 133-137.
11. Canadian Pediatric Society: Antifungal agents for common paediatric infection. Can. J. Infect. Dis. Med. Microbiol. 2008; 19: 15-18.
12. Rotta I., Ziegelmann P.K., Otuki M.F. et al.: Efficacy of topical antifungals in the treatment of dermatophytosis: a mixed-treatment comparison meta-analysis involving 14 treatments. JAMA Dermatol. 2013; 149: 341-349.
13. Budimulja U., Bramono K., Urip K.S. et al.: Once daily treatment with terbinafine 1% cream (Lamisil) for one week is effective in the treatment of tinea corporis and cruris. A placebo-controlled study. Mycoses 2001; 44: 300-306.
14. El-Gohary M., van Zuuren E.J., Fedorowicz Z. et al.: Topical antifungal treatments for tinea cruris and tinea corporis. Cochrane Database Syst. Rev. 2014; 4: CD009992.
15. Shivakumar V., Okade R., Rajkumar V. et al.: Intermittent pulse-dosed terbinafine in the treatment of tinea corporis and/or tinea cruris. Indian J. Dermatol. 2011; 56: 121-122.
16. Farag A., Taha M., Halim S.: One-week therapy with oral terbinafine in cases of tinea cruris/corporis. Br. J. Dermatol. 1994; 131: 684-686.
17. Lesher J.I. Jr. Oral therapy of common superficial fungal infection of the skin. J. Am. Acad. Dermatol. 1999; 40: S31-34.
18. Sahoo A.K., Mahajan R.: Management of tinea corporis, tinea cruris, and tinea pedis: a comprehensive review. Indian Dermatol. Online J. 2016; 7: 77-86.
19. Sonthalia S., Singal A., Das S.: Tinea cruris and tinea corporis masquerading as tinea indecisiva: case report and review of the literature. J. Cutan. Med. Surg. 2014; 18: 1-6.
20. Rich P., Houpt K.R., LaMarca A. et al.: Safety and efficacy of short-duration oral terbinafine for the treatment of tinea corporis or tinea cruris in subjects with HIV infection or diabetes. Cutis. 2001; 68(1 Supl.): 15-22.
21. Elewski B., Smith S.: The safety and efficacy of terbinafine in patients with diabetes and patients who are HIV positive. Cutis 2001; 68(1 Supl.): 23-29.
22. Shiraki Y., Hiruma M., Inoue A. et al.: A short-term treatment of tinea corporis and tinea cruris with oral terbinafine. Nihon Ishinkin Gakkai Zasshi 2003; 44: 121-125.
23. McClellan K.J., Wiseman L.R., Markham A.: Terbinafine. An update of its use in superficial mycoses. Drugs 1999; 58: 179-202.
24. Patel G.A., Wiederkehr M., Schwartz R.A.: Tinea cruris in children. Cutis 2009; 84: 133-137.
2. Rotsztejn H., Zalewska A.: Superficial tinea infections of the genital region in women. Przegl. Menopauz. 2005; 4: 65-67.
3. Kaszuba A., Adamski Z.: Leksykon dermatologiczny. Wyd. I. Czelej, Lublin 2011.
4. Iwanaga T., Ushigami T., Anzawa K., Mochizuki T.: Pathogenic Dermatophytes Survive in Nail Lesions During Oral Terbinafine Treatment for Tinea Unguium. Mycopathologia 2017. DOI: 10.1007/s11046-017-0118-8 [Epub ahead of print].
5. Maleszka R., Adamski Z., Szepietowski J., Baran E.: Leczenie powierzchownych zakażeń grzybiczych – rekomendacje ekspertów Sekcji Mikologicznej Polskiego Towarzystwa Dermatologicznego. Przegl. Dermatol. 2015; 102: 305-315.
6. Hasse-Cieślińska M.: Diagnostyka i leczenie powierzchownych zakażeń grzybiczych. Przew. Lek. 2006; 7: 109-120.
7. Hasse-Cieślińska M.: Nowoczesne leki stosowane w terapii dermatomikoz. Przew. Lek. 2004; 6: 70-77.
8. Maleszka R., Adamski Z.: Leki przeciwgrzybicze w codziennej praktyce lekarskiej. Przew. Lek. 2001; 4: 48-56.
9. Khoza S., Moyo I., Ncube D.: Comparative hepatotoxicity of fluconazole, ketoconazole, itraconazole, terbinafine, and griseofulvin in rats. J. Toxicol. 2017; 2017: 6746989.
10. Patel G.A., Wiederkehr M., Schwartz R.A.: Tinea cruris in children. Cutis. 2009; 84: 133-137.
11. Canadian Pediatric Society: Antifungal agents for common paediatric infection. Can. J. Infect. Dis. Med. Microbiol. 2008; 19: 15-18.
12. Rotta I., Ziegelmann P.K., Otuki M.F. et al.: Efficacy of topical antifungals in the treatment of dermatophytosis: a mixed-treatment comparison meta-analysis involving 14 treatments. JAMA Dermatol. 2013; 149: 341-349.
13. Budimulja U., Bramono K., Urip K.S. et al.: Once daily treatment with terbinafine 1% cream (Lamisil) for one week is effective in the treatment of tinea corporis and cruris. A placebo-controlled study. Mycoses 2001; 44: 300-306.
14. El-Gohary M., van Zuuren E.J., Fedorowicz Z. et al.: Topical antifungal treatments for tinea cruris and tinea corporis. Cochrane Database Syst. Rev. 2014; 4: CD009992.
15. Shivakumar V., Okade R., Rajkumar V. et al.: Intermittent pulse-dosed terbinafine in the treatment of tinea corporis and/or tinea cruris. Indian J. Dermatol. 2011; 56: 121-122.
16. Farag A., Taha M., Halim S.: One-week therapy with oral terbinafine in cases of tinea cruris/corporis. Br. J. Dermatol. 1994; 131: 684-686.
17. Lesher J.I. Jr. Oral therapy of common superficial fungal infection of the skin. J. Am. Acad. Dermatol. 1999; 40: S31-34.
18. Sahoo A.K., Mahajan R.: Management of tinea corporis, tinea cruris, and tinea pedis: a comprehensive review. Indian Dermatol. Online J. 2016; 7: 77-86.
19. Sonthalia S., Singal A., Das S.: Tinea cruris and tinea corporis masquerading as tinea indecisiva: case report and review of the literature. J. Cutan. Med. Surg. 2014; 18: 1-6.
20. Rich P., Houpt K.R., LaMarca A. et al.: Safety and efficacy of short-duration oral terbinafine for the treatment of tinea corporis or tinea cruris in subjects with HIV infection or diabetes. Cutis. 2001; 68(1 Supl.): 15-22.
21. Elewski B., Smith S.: The safety and efficacy of terbinafine in patients with diabetes and patients who are HIV positive. Cutis 2001; 68(1 Supl.): 23-29.
22. Shiraki Y., Hiruma M., Inoue A. et al.: A short-term treatment of tinea corporis and tinea cruris with oral terbinafine. Nihon Ishinkin Gakkai Zasshi 2003; 44: 121-125.
23. McClellan K.J., Wiseman L.R., Markham A.: Terbinafine. An update of its use in superficial mycoses. Drugs 1999; 58: 179-202.
24. Patel G.A., Wiederkehr M., Schwartz R.A.: Tinea cruris in children. Cutis 2009; 84: 133-137.